I'm LongbridgeAI, I can summarize articles.TJBE plans to acquire 100% equity of Cangzhou Xuyang and will resume trading on May 19, 2025. This transaction involves issuing shares to Xuyang Group and raising supporting funds. Cangzhou Xuyang is the world's second-largest caprolactam company, with a complete industrial chain and strong profitability. After the transaction, TJBE will form a dual main business development of "anode materials + nylon new materials," which will help enhance the company's asset scale and core competitiveness, promoting high-quality development
According to the announcement from Binhai Energy (000695.SZ), the company plans to issue shares to purchase a total of 100% equity of Cangzhou Xuyang from Xuyang Group, Xuyang Coal Chemical, Shenzhen Capital Group New Materials Fund, and Agricultural Bank of China Asset Management. At the same time, Binhai Energy intends to privately issue shares to no more than 35 qualified specific investors to raise matching funds. The company's stock will resume trading on May 19, 2025 (Monday) at the market opening.
The target company, Cangzhou Xuyang, is a national high-tech enterprise primarily engaged in the production of nylon new materials, with products mainly covering caprolactam, nylon 6, and nylon elastomers. According to the 2024 data statistics from Frost & Sullivan, the target company is the second-largest caprolactam enterprise in the world. Cangzhou Xuyang has an integrated industrial chain that includes hydrogen production, hydrogen peroxide, cyclohexanone, and the preparation of caprolactam, hexamethylenediamine, and nylon 6, nylon elastomers, making it one of the few companies in China with a complete process flow. It has good profitability and outstanding technological innovation advantages.
This transaction is an important integration measure for the actual controller to inject high-quality chemical new materials business into the listed company. After the transaction is completed, the listed company will add nylon new materials business, including caprolactam, nylon 6, and nylon elastomers, forming a dual main business development pattern of "anode materials + nylon new materials." This is beneficial for the company to expand its business territory, create a second growth curve, enhance the asset scale, operating income, and net profit level of the listed company, strengthen the company's risk resistance and core competitiveness, and improve the sustainable development capability of the listed company, effectively safeguarding the interests of minority shareholders and promoting the high-quality development of the listed company